BofA analyst Tim Anderson lowered the firm’s price target on Johnson & Johnson to $160 from $166 and keeps a Neutral rating on the shares.
Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...
Johnson & Johnson has underperformed its large-cap healthcare peers and the S&P 500, with an -8% decline over the past year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback